Treatment Sequence for Osteoporosis

Felicia Cosman,Bente Langdahl,Benjamin Leder

DOI: https://doi.org/10.1016/j.eprac.2024.01.014

IF: 3.701

2024-02-04

Endocrine Practice

Abstract:Osteoporosis is a chronic progressive disease which requires lifelong monitoring and treatment. Sequencing from one treatment to another at different ages and stages of disease is an approach which can maximize benefits and avoid potential risks from long-term treatment with a single agent. When medications are discontinued, in the absence of sequential therapy, bone turnover rates return to baseline or above baseline and bone loss occurs. The rate of bone loss differs for different treatments, with a very slow decline after stopping bisphosphonates and a particularly rapid decline after stopping denosumab. Careful attention to osteoporosis medication transitions can mitigate bone density loss and its consequences. This paper reviews data in postmenopausal women that evaluate the effects of antiresorptive agents followed by other antiresorptives, osteoanabolic agents followed by antiresorptives and antiresorptives followed by osteoanabolic medications. For women who remain at high risk, switching from bisphosphonates to the more potent antiresorptive, denosumab, will result in further improvement in BMD. When indicated, stopping denosumab can be accomplished safely by transition to an adequate bisphosphonate regimen. For high and very high-risk patients, treating with osteoanabolic agents first, followed by antiresorptive agents, produces substantially larger BMD gains than the reverse treatment sequence, with the biggest differences seen for bone density of the hip. Awareness of the importance of treatment sequence can help improve osteoporosis care across the postmenopausal lifespan.

endocrinology & metabolism